glp·helper
glphelper.com/wegovy/california/fountain-valley
GLP-1 receptor agonistFDA-approved June 2021Rx · Subcutaneous injection · Once weekly

Wegovy® providers &
prescriptions in Fountain Valley, CA

Verified Wegovy providers in Fountain Valley, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Wegovy weight loss →trial-anchored estimate
city providers
31
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
32 of 32 shown

Find an Wegovy provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /wegovy/california/{city}
§ 03Getting Wegovy in Fountain Valley
32 providers · Fountain Valley, CA

How to get Wegovy in Fountain Valley.

32 GLP-1 prescribers and 7 local resource types are on record for Fountain Valley, plus 3 nearby towns in the directory.

Prescribers in Fountain Valley
32 prescribers
32 GLP-1 prescribers in Fountain Valley, most listed as Family Medicine (15), Internal Medicine (13) and Internal Medicine, Endocrinology, Diabetes & Metabolism (3). Any California-licensed physician, nurse practitioner, or PA can prescribe Wegovy, over video or in person. The nearest towns on record are Huntington Beach (33 providers), Costa Mesa (31 providers) and Santa Ana (29 providers).
Around the prescription in Fountain Valley
7 listed nearby
25 dietitians, 2 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 62 places to move are on record near Fountain Valley.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Ozempic, higher dose.

Wegovy is the brand name for semaglutide at the higher 2.4 mg dose. It is the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]

In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9%, roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]

At a glanceNDC 0169-4525
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
June 2021
Approved use
Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Off-label use
Off-label use is uncommon. Ozempic is the FDA-approved formulation for type 2 diabetes
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Fountain Valley

Fountain Valley, California has a population of 57,047 people. The adult obesity rate in Fountain Valley is an age-adjusted estimate of 20.7%, 8.4 percentage points below the California state rate of 29.1%. Diagnosed diabetes reaches 9.7% of adults in Fountain Valley. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 22% of adults in Fountain Valley.

of Fountain Valley adults have obesity
20.7%
diagnosed diabetes
9.7%
no regular physical activity
22%

Age-adjusted estimates for Fountain Valley, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossGLP-1s during menopause
§ 05Support around Wegovy in Fountain Valley
6 fitness clubs

The prescription is one part. Here is the rest, in Fountain Valley.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Fountain Valley, CA, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

GYM
FITNESS
5.0 on Google · 20 reviews
17233 Newhope St Unit C
Planet Fitness
GYM
4.0 on Google · 730 reviews
16201 S Harbor Blvd
Website
Movement Fountain Valley
GYM
4.2 on Google · 191 reviews
18030 Newhope St
Website
Taurus MMA
BOXING
5.0 on Google · 62 reviews
9120 Edinger Ave
Website
Bruce Performance Aesthetics
TRAINING
5.0 on Google · 39 reviews
18289 Mt Baldy Cir
Website
BW Personal Training
TRAINING
5.0 on Google · 37 reviews
8894 Warner Ave
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Carol Adams, R.D
RD
Registered dietitian
11250 Warner Ave
Call 714-513-5506NPI 1164466207
Linda Araki, R.D
RD
Registered dietitian
17100 Euclid St
Call 714-966-7200NPI 1184802373
Silje Bjorndal, M.S.,R.D
RD
Registered dietitian
9920 Talbert Ave
Call 714-378-7033NPI 1386083475
Mona Lisa Collado, RDN
RD
Registered dietitian
9920 Talbert Ave
Call 714-378-7033NPI 1821676214
Jessica Defalco, RD
RD
Registered dietitian
17360 Brookhurst St
Call 714-822-1334NPI 1992429526
Katherine Haghighi, R.D
RD
Registered dietitian
18111 Brookhurst St. Suite 5600
Call 714-861-4666NPI 1497121636
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize results from the STEP program, the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication, and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.

STEP-1 randomized 1,961 adults with obesity to weekly 2.4 mg semaglutide vs placebo over 68 weeks. Mean body-weight reduction was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of patients on semaglutide achieved ≥ 5% weight loss vs 31.5% on placebo.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
Weight change
−14.9%
vs −2.4% placebo, 68 wk[4]
≥ 5% weight loss
86.4%
vs 31.5% placebo[4]
≥ 15% weight loss
50.5%
vs 4.9% placebo[4]
Major adverse cardiac events
−20%
HR 0.80 vs. placebo (SELECT)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Wegovy weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
44%
mild
More common than at Ozempic doses; usually transient and dose-dependent
Diarrhea
30%
mild
Most frequent during dose escalation phase
Vomiting
24%
mild
Slower titration reduces incidence
Constipation
24%
mild
Hydration + fiber recommended
Abdominal pain
20%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; class warning
Gallbladder disease
1.6%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$1,300 to $1,500
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $400
per month copay
Varies by PBM; many plans require BMI ≥ 30 + step therapy
Commercial insurance (denied)
Typically denied
Most plans exclude weight-loss medications from formulary
Medicare Part D
Not covered
Statutory exclusion of weight-loss drugs in original Medicare[5]
Manufacturer savings card
as low as $0
per month for 12 mo
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Wegovy providers in California

NPI-verified Wegovy (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Wegovy in other states

Find NPI-verified Wegovy (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Wegovy in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]